These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34505877)

  • 1. Psoriatic arthritis: what to do when everything fails?
    Seara V; Ferro A; Marinho A
    Rheumatology (Oxford); 2021 Dec; 61(1):e19-e21. PubMed ID: 34505877
    [No Abstract]   [Full Text] [Related]  

  • 2. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
    Coates LC; Garrood T; Gullick N; Helliwell P; Kent T; Marks J; Tillett W; Kaur-Papadakis D; Tahir H; van Haaren S; McInnes I
    Rheumatology (Oxford); 2022 Dec; 62(1):e1-e3. PubMed ID: 35799375
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
    N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
    Valenti M; Facheris P; Pavia G; Gargiulo L; Borroni RG; Costanzo A; Narcisi A
    Dermatol Ther; 2020 Jul; 33(4):e13708. PubMed ID: 32474988
    [No Abstract]   [Full Text] [Related]  

  • 5. Psoriatic arthritis.
    Durham LE; Taams LS; Kirkham BW
    Br J Hosp Med (Lond); 2016 Jul; 77(7):C102-8. PubMed ID: 27388392
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis.
    Hernandez Bel L; Hernández Garfella ML; Chiarri Toumit C; Valenzuela Oñate C
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):621-622. PubMed ID: 30100239
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
    Landewé R; Ritchlin CT; Aletaha D; Zhang Y; Ganz F; Hojnik M; Coates LC
    Rheumatology (Oxford); 2019 Jun; 58(6):1025-1033. PubMed ID: 30608620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
    Behrens F; Koehm M; Schwaneck EC; Schmalzing M; Wittig BM; Gnann H; Greger G; Tony HP; Burkhardt H
    Scand J Rheumatol; 2019 Sep; 48(5):375-382. PubMed ID: 31311386
    [No Abstract]   [Full Text] [Related]  

  • 12. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
    Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
    J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy.
    Ramos MI; Teunissen MB; Helder B; Aarrass S; de Hair MJ; van Kuijk AW; Gerlag DM; Tak PP; Lebre MC
    Rheumatology (Oxford); 2016 Sep; 55(9):1575-84. PubMed ID: 27179104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regarding Mastorino et al.'s 'Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'.
    Yu S; Wei JC
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1388-e1389. PubMed ID: 37458245
    [No Abstract]   [Full Text] [Related]  

  • 16. 'Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'-response to Yu et al.
    Mastorino L; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):e175-e176. PubMed ID: 37708568
    [No Abstract]   [Full Text] [Related]  

  • 17. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Gender on the Persistence of Different Tumor Necrosis Factor Inhibitor Treatments in Patients With Psoriatic Arthritis.
    García-Porrúa C; Iñiguez-Ubiaga CL; Pinto-Tasende JA
    J Rheumatol; 2024 Apr; 51(4):434-436. PubMed ID: 38101912
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.